Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07409636 · ClinicalTrials.gov registry record
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 11,991
- Enrollment target
NCT07409636: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07409636 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 11,991 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07409636 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 11,991 participants
- Enrollment target
Study Summary
The purpose of this study was to describe the effectiveness of inclisiran and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in the real-world setting in China. Data for this study was obtained from three regional electronic health record (rEHR) databases and included patients who met the enrollment requirements during the study identification period (October 1, 2023 to June 30, 2024) who had used either inclisiran or PCSK9 mAb for the first time. The retrospective data up to the date of ethics committee (EC) approval was extracted from multiple rEHR databases to generate study-specific datasets supporting this study on respective secure data analysis platforms. Due to the requirements of data security policies, the patient-level data from rEHR databases could not be transferred out of the secure platform. Thus, independent analysis based on data from each of the three databases was performed separately and meta-analysis was conducted to integrate one result of all independent data analyses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,991 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-12-22 |
What the finished NCT07409636 record still lists
NCT07409636 is an observational study that tracks outcomes without assigning an intervention. Its 11,991 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07409636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07409636 about?
NCT07409636 is a clinical study titled "A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients". The purpose of this study was to describe the effectiveness of inclisiran and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in the real-world setting in China. Data for this study was obtained from three regional electronic health record (rEHR) databases and inc...
What is the current status of trial NCT07409636?
This trial is currently completed. The enrollment target is 11,991 participants. The study started on 2025-01-23. Estimated completion is 2025-12-22.
Who is sponsoring clinical trial NCT07409636?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI